Efficacy and Safety Evaluation of Microfocused Ultrasound Combined With 1550 nm Non-Ablative Fractional Laser for Facial Rejuvenation
NCT ID: NCT07107308
Last Updated: 2025-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
25 participants
INTERVENTIONAL
2024-11-01
2025-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Both the researchers and the subjects were in an open state. The researchers measured and evaluated various indicators of the patients' skin. Patients diagnosed with facial photoaging underwent VISIA photography, digital camera photography, non-invasive skin testing, dermoscopy testing and high-frequency skin ultrasound testing after enrollment. On the day of enrollment, micro-focused ultrasound (using treatment heads S1.5, S2, N3, N4.5, P1.5, P2.0, P3.0, and P4.5) was performed on both sides of the face once. One side of the face was randomly selected as the experimental side, and a 1550 nm non-ablative fractional laser treatment was performed immediately after the micro-focused ultrasound treatment once. For the second treatment, micro-focused ultrasound (using S1.5, S2, P1.5, and P2.0 treatment heads) was performed on both sides once. The experimental side was treated with 1550 nm non-ablative fractional laser once immediately after the micro-focused ultrasound treatment.
The research period was May, including a treatment period of 2 months. Follow-up was conducted every two weeks for a total of 10 times, all of which were on-site visits. The grace period during the visit is ±3 days.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Long-term Effects of Microfocused Ultrasound on Facial Tightening Using Quantitative Instruments
NCT06286384
Efficacy and Safety of 1565-nm Non-ablative Fractional Laser Versus Long-pulsed 1064-nm Nd:YAG Laser in the Treatment of Enlarged Facial Pores
NCT05360043
The Efficacy of Microfocused Ultrasound Technique in the Treatment of Facial Skin Laxity
NCT06449911
Soluble Hyaluronic Acid Microneedle VS. Non-ablative Fractional Laser on Infraorbital Wrinkles.
NCT04989361
A Study of the Efficacy of Erbium:YAG 2940nm in Combination With 1064nm Laser on Facial Rejuvenation
NCT03962621
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study adopted the research method of a single-center case-control study. According to the inclusion and exclusion criteria, 25 patients with facial photoaging were included. The assessment and follow-up of various skin indicators of the patients were conducted before and after the treatment. Both the researchers and the subjects were in an open state. The researchers measured and evaluated various indicators of the patients' skin.
1. Preparatory work: Twenty-five volunteers with photoaging of the skin who met the inclusion criteria were recruited. After the first diagnosis, the informed consent form was signed. The basic information of the patients (age, gender, skin type, nature of work, sun exposure time, expression habits, etc.) was recorded. Digital photos of the front, 45-degree left and right sides, and 90-degree left and right sides were taken manually. The pictures were collected using the VISIA skin detector. The thickness of the dermis at the nasolabial sulcus was measured by skin ultrasound, and dermoscopy was performed. Non-invasive skin physiological indices were measured: skin elasticity, TEWL, EI, MI, and L\*a\*b\* values (the average value was calculated by taking three points from different parts). Meanwhile, the patients underwent self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) scores.
2. Treatment process: Micro-focused ultrasound (using treatment heads S1.5, S2, N3, N4.5, P1.5, P2.0, P3.0, and P4.5) was performed once on both sides of the face. One side of the face was randomly selected as the experimental side. Immediately after the micro-focused ultrasound treatment, a 1550 nm non-ablative fractional laser (with a dot spacing of 0.75-1.25mm) was performed. Energy: 10-20 MJ. Repeat the treatment twice. The endpoint reaction is mild erythema and edema at the treatment site. Treat once. The second treatment was conducted 6 weeks after the first treatment. Micro-focused ultrasound treatment (using S1.5, S2, P1.5, and P2 treatment heads) was performed on both sides once. On the experimental side, 1550 nm non-ablative fractional laser (with a dot spacing of 0.75-1.25mm and an energy of 10-20mj) was performed immediately after micro-focused ultrasound treatment. The treatment was repeated twice. The endpoint response was mild erythema and edema at the treatment site (treated once). A total of 2 treatments were conducted. Use the moisturizing mask continuously for three days after each treatment. After the first diagnosis and the end of follow-up, the patients underwent Self-Rating Anxiety Scale (SAS) and Zong's Self-Rating Depression Scale (SDS) scores. The daily basic care products used by all patients were facial cleanser + simple moisturizer + sunscreen.
3. Follow-up: Follow-up was conducted before each treatment, 2 weeks after the end of the first treatment, 4 weeks after the end of the first treatment, and 2 weeks, 4 weeks, 6 weeks, and 12 weeks after the end of all treatments. During the follow-up, VISIA photography, digital camera photography, dermoscopy detection, high-frequency ultrasound detection of the skin and non-invasive skin detection were performed: skin elasticity, EI, MI, L\*a\*b\* value, TEWL value. Self-rating Anxiety Scale (SAS) and Zong's Self-Rating Depression Scale (SDS) scores were conducted at the end of the first diagnosis and all follow-ups.
Record any adverse events during the trial, any laser and drug adverse reactions, the reasons for withdrawal from the trial, and any clinically significant abnormalities from baseline to the end of follow-up for safety evaluation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Microfocused Ultrasound Device (MFUpro, Zhengzhou, China)
Microfocused Ultrasound
Before treatment, clean the treatment area, mark the treatment zone, and evenly apply a layer of ultrasound coupling agent about the thickness of a coin on the treatment area. The patient's face was treated with S1.5, S2, N3, N4.5, P1.5, P2.0, P3.0 and P4.5 treatment heads respectively. After the treatment, the face was cleaned and a medical mask was applied for 15 minutes. After the treatment, attention was paid to moisturizing and sun protection.
Erbium-Doped Fiber Laser Therapeutic Device(FraxStar ShenGuang 1550, Beijing, China)
Erbium-Doped Fiber Laser
Doctors and patients wear corresponding protective glasses. Apply cold gel to the treatment area on the patient's face and select certain treatment parameters based on the patient's skin lesion condition and skin type. After the treatment, clean your face. Decide whether to apply ice based on the severity of the skin lesion reaction. If ice application is necessary, the regular ice application time is 15 to 30 minutes, and apply a medical mask for 15 minutes. After the treatment, pay attention to moisturizing and sun protection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Microfocused Ultrasound
Before treatment, clean the treatment area, mark the treatment zone, and evenly apply a layer of ultrasound coupling agent about the thickness of a coin on the treatment area. The patient's face was treated with S1.5, S2, N3, N4.5, P1.5, P2.0, P3.0 and P4.5 treatment heads respectively. After the treatment, the face was cleaned and a medical mask was applied for 15 minutes. After the treatment, attention was paid to moisturizing and sun protection.
Erbium-Doped Fiber Laser
Doctors and patients wear corresponding protective glasses. Apply cold gel to the treatment area on the patient's face and select certain treatment parameters based on the patient's skin lesion condition and skin type. After the treatment, clean your face. Decide whether to apply ice based on the severity of the skin lesion reaction. If ice application is necessary, the regular ice application time is 15 to 30 minutes, and apply a medical mask for 15 minutes. After the treatment, pay attention to moisturizing and sun protection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female patients aged 30 to 60 years old;
3. Patients with Fitzpatrick9 skin wrinkle grades I to III;
4. Patients who voluntarily participate and sign the informed consent form.
Exclusion Criteria
2. There are mobile or metal implants on the face;
3. Severe or cystic acne on the face;
4. There was a history of facial injection or surgery within 6 months before the trial;
5. Severe keloid constitution;
6. There is a history of allergy to local anesthetics, iodophor or photosensitivity.
7. Have a history of bleeding tendency;
8. Suffering from serious skin diseases such as skin tumors;
9. Suffering from autoimmune diseases, systemic diseases or mental disorders;
10. Women who are planning to become pregnant, are pregnant or breastfeeding;
11. There is a frequent need for makeup;
12. There is a long-term need for outdoor work and sun protection is not possible.
13. Patients with poor compliance, which affects clinical efficacy and the judgment of adverse reactions.
30 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital of Xi'an Jiaotong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Weihui Zeng
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The second affiliated hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.